Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis.

CONCLUSION: Secukinumab treatment was associated with a low (<1%) incidence of immunogenicity in PsA and AS patients.
PMID: 31203228 [PubMed - as supplied by publisher]

Source: J Rheumatol - June 14, 2019 Category: Rheumatology Authors: Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J, Shete A, Bruin G Tags: J Rheumatol Source Type: research